Evommune Inc., Completes $83 Million Series A Financing To Advance Development Of Unique Chronic Inflammation Pipeline
Evommune Inc., Completes $83 Million Series A Financing To Advance Development Of Unique Chronic Inflammation Pipeline
09/09/21, 11:31 AM
Location
los altosMoney raised
$83 million
Round Type
series a
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced the completion of an $83 million Series A financing which included Andera Partners and LSP, who joined forces with a global syndicate of investors and existing investor, Pivotal bioVenture Partners. The financing enables Evommune to continue the research and development of transformative therapies through both industry and academic collaborations to treat patients with immune-mediated and chronic inflammatory diseases.
Company Info
Location
los altos, california, united states
Additional Info
Evommune is a private R&D company and innovation engine in chronic inflammation. The company is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, Calif. For more information, please visit Evommune.com.